Compare Wahed FTSE USA Shariah ETF (HLAL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

HLAL trades at $70.22, down 0.17% on the day, reflecting modest near-term pressure. Key financial ratios such as P/E, P/S, and ROE are not available in the current dataset, limiting fundamental visibility. A dividend of $0.02 is scheduled for June 2026, indicating a long-term income component. Trading volume and technical levels require additional market data for full context.

The outlook for HLAL hinges on upcoming financial disclosures to assess valuation and profitability. Investment opportunity lies in potential earnings growth and dividend yield, but risks include lack of current fundamental data and market volatility. Investors should await SEC filings for a clearer picture of the company's financial health.

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.